13th Annual Fall Midwest Thoracic and GI Oncology Conference
Playback speed
10 seconds
Targeting ALK in NSCLC: Alectinib 1st Line Treatment Choice, New Promising Inhibitor, and ALK Inhibitor + IO Toxic Combo
362 views
December 19, 2018
Login to view comments.
Click here to Login
Lung